Literature DB >> 1649371

Visualization of a dopamine D1 receptor mRNA in human and rat brain.

G Mengod1, M T Vilaró, H B Niznik, R K Sunahara, P Seeman, B F O'Dowd, J M Palacios.   

Abstract

Using 32P-labeled oligonucleotides derived from the coding region of human dopamine D1 receptor mRNA we have localized in the human and rat brain the cells containing the mRNAs coding for this receptor. Dopamine D1 receptor mRNA in human brain was found to be contained in the neurons of the caudate and putamen nuclei as well as in the nucleus accumbens, some cortical regions and some nuclei of the amygdala. In the rat brain, cells containing D1 receptor mRNA were enriched in caudate-putamen and accumbens nuclei, olfactory tubercle, islands of Calleja, some cortical areas and in several thalamic nuclei. Moreover, in both species, it was absent from the neurons of the substantia nigra both pars compacta and pars reticulata and ventral tegmental area as well as from the globus pallidus pars lateralis and medialis in human and globus pallidus and entopeduncular nucleus in rat. In general, a good agreement was found with the distribution of binding sites labeled with the D1 antagonist SCH 23390. The main exception was the absence of D1 receptor mRNA in globus pallidus and substantia nigra, regions where high densities of receptor sites are found. These data support the notion that sites in these two regions are localized to projections from striatal neurons and that dopaminergic neurons do not express this receptor.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1649371     DOI: 10.1016/0169-328x(91)90110-j

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  11 in total

Review 1.  Dopamine receptor genes: new tools for molecular psychiatry.

Authors:  H B Niznik; H H Van Tol
Journal:  J Psychiatry Neurosci       Date:  1992-10       Impact factor: 6.186

2.  Alternative splicing generates metabotropic glutamate receptors inducing different patterns of calcium release in Xenopus oocytes.

Authors:  J P Pin; C Waeber; L Prezeau; J Bockaert; S F Heinemann
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

Review 3.  Functional genomics strategies to identify susceptibility genes and treatment targets in alcohol dependence.

Authors:  Markus Heilig; Wolfgang Sommer
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

Review 4.  Pharmacology of signaling induced by dopamine D(1)-like receptor activation.

Authors:  Ashiwel S Undieh
Journal:  Pharmacol Ther       Date:  2010-06-12       Impact factor: 12.310

Review 5.  The external globus pallidus: progress and perspectives.

Authors:  Daniel J Hegeman; Ellie S Hong; Vivian M Hernández; C Savio Chan
Journal:  Eur J Neurosci       Date:  2016-03-28       Impact factor: 3.386

6.  Comparative Ultrastructural Analysis of D1 and D5 Dopamine Receptor Distribution in the Substantia Nigra and Globus Pallidus of Monkeys.

Authors:  Michele A Kliem; Jean-Francois Pare; Zafar U Khan; Thomas Wichmann; Yoland Smith
Journal:  Adv Behav Biol       Date:  2009-08-21

Review 7.  Autoradiographical and immunohistochemical analysis of receptor localization in the central nervous system.

Authors:  J G Chabot; S Kar; R Quirion
Journal:  Histochem J       Date:  1996-11

8.  Calcium-dependent, D2 receptor-independent induction of c-fos by haloperidol in dopamine neurons.

Authors:  C Jomphe; D Lévesque; L-E Trudeau
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-04-15       Impact factor: 3.000

9.  Localization of D1 and D2 dopamine receptors in brain with subtype-specific antibodies.

Authors:  A I Levey; S M Hersch; D B Rye; R K Sunahara; H B Niznik; C A Kitt; D L Price; R Maggio; M R Brann; B J Ciliax
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

10.  Regulation of dopamine D₃ receptor in the striatal regions and substantia nigra in diffuse Lewy body disease.

Authors:  J Sun; N J Cairns; J S Perlmutter; R H Mach; J Xu
Journal:  Neuroscience       Date:  2013-06-01       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.